InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,199.60
(
0.13%
)
Dow Jones
39,112.16
(
0.00%
)
Brent Oil
84.75
(
0.67%
)
Bitcoin
61,465.11
(
-0.56%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: None

Saturday, 05/04/2013 11:22:34 AM

Saturday, May 04, 2013 11:22:34 AM

Post# of 80490
Maybe this explains meeting with NVS...

http://www.ncbi.nlm.nih.gov/pubmed/23539538

Midostaurin has been in the lab for over 10 years, still not approved for an indication. Appears to overlap with several Pona targets, FLT-3, c-KIT, VEGFR-2, PDGFR . Most current trials are combo studies with chemo in AML.

Latest trial results from ASH 2012 leave something to be desired:
https://ash.confex.com/ash/2012/webprogram/Paper48129.html

I think we will see many more Pona combos as labs around the world understand Pona just makes their drugs better. I sense a nice revenue stream flowing with little to no outlay.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up